Search
Clinician Ordering Portal
Scientific Evidence
Independent validation of TissueCypher to predict progression in community- based Barrett's esophagus with low grade dysplasia: analysis in a completed prospective study
May 2020
TissueCypher stratified BE patients with a community-based diagnosis of LGD with diagnostic accuracy comparable to three renowned expert pathologists.
Publication: Podium presentation (1085) at DDW 2020, Virtual
A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus
Oct 2019
The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.
Publication: ClinicoEconomics and Outcomes Research
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio
Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus
Oct 2019
TissueCypher may be a effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.
Publication: Poster presentation (371) at ACG 2019, San Antonio
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (P1990) at UEG 2019, Barcelona
A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus
Oct 2019
The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.
Publication: ClinicoEconomics and Outcomes Research
Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus
Oct 2019
TissueCypher may be an effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.
Publication: Poster presentation (371) at ACG 2019, San Antonio
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio
Independent validation of a tissue systems pathology test to predict progression in Barrett’s esophagus patients
May 2019
TissueCypher identifies NDBE patients who are at increased risk for progression to HGD/EAC and may benefit from increased surveillance or early intervention.
Publication: Podium presentation (1068) at DDW 2019, San Diego
Clinical experience with a multiplexed immunofluorescence tissue biomarker assay (Tissue Cypher BE) in the management of Barrett’s esophagus: a single center experience
Jun 2018
Use of TissueCypher resulted in clinical “upstaging” occurred in 5 of 46 cases, leading to treatment that otherwise might not be pursued.
Publication: Poster presentation (Su1109) at DDW 2018, Washington DC
Clinical experience with a multiplexed immunofluorescence tissue biomarker assay (Tissue Cypher BE) in the management of Barrett’s esophagus: a single center experience
Jun 2018
Use of TissueCypher resulted in clinical “upstaging” occurred in 5 of 46 cases, leading to treatment that otherwise might not be pursued.
Publication: Poster presentation (Su1109) at DDW 2018, Washington DC
Systems biology approaches in cancer pathology
Jan 2018
A method for objective quantification of epithelial and stromal biomarkers to generate a tissue profile aiding predictive models for cancer pathology.
Publication: Methods in Molecular Biology